Abstract: There is provided a method for the isolation and cultivation of mesenchymal stem/progenitor cells from umbilical cord blood, and also to a method for the differentiation of the umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues. The method include overlaying umbilical cord blood onto Ficoll-Hypaque solution; centrifuging the umbilical cord blood on the Ficoll-Hypaque solution to obtain a mononuclear cell layer; reacting cells obtained by monolayer culture of the mononuclear cells with antibodies to mesenchymal stem/progenitor cell-specific antigens for a predetermined period of incubation time; isolating only cells bound to their corresponding antibodies using a cell sorter; and cultivating the isolated cells, thereby obtaining mesenchymal stem/progenitor cells with high purity and excellent viability.

Abstract: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.

Abstract: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.

Abstract: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.

Abstract: Disclosed herein is a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention includes (i) cellular components separated, proliferated, and/or differentiated from the umbilical cord blood, (ii) a culture medium; and (iii) a biocompatible polymer. The composition has very superior ability of proliferation and differentiation and easier to be collected and acquired.

Abstract: The present application discloses a method for expanding a population of mammalian cells comprising contacting the cells with angiopoietin 1.

Abstract: The present invention relates to a method for the isolation and cultivation of mesenchymal stem/progenitor cells from umbilical cord blood, and also to a method for the differentiation of the umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues. The method comprises the steps of: overlaying umbilical cord blood onto Ficoll-Hypaque solution; centrifuging the umbilical cord blood on the Ficoll-Hypaque solution to obtain a mononuclear cell layer; reacting cells obtained by monolayer culture of the mononuclear cells with antibodies to mesenchymal stem/progenitor cell-specific antigens for a predetermined period of incubation time; isolating only cells bound to their corresponding antibodies using a cell sorter; and cultivating the isolated cells, thereby obtaining mesenchymal stem/progenitor cells with high purity and excellent viability.

Abstract: The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention is characterized by that it is composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media, and biocompatible polymers. Compared to the conventional cells used for the treatment of articular cartilage damage, cellular components of the composition of the present invention have very superior ability of proliferation and differentiation and more easy to be collected and acquired.